Allergan Inc Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for ALLERGAN INC, and when can generic versions of ALLERGAN INC drugs launch?
ALLERGAN INC has one approved drug.
There are nine US patents protecting ALLERGAN INC drugs.
There are one hundred and forty-five patent family members on ALLERGAN INC drugs in thirty-two countries and three supplementary protection certificates in three countries.
Summary for Allergan Inc
| International Patents: | 145 |
| US Patents: | 9 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 4 |
| Patent Litigation for Allergan Inc: | See patent lawsuits for Allergan Inc |
Drugs and US Patents for Allergan Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | 9,492,316 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | 10,398,707 | See Plans and Pricing | See Plans and Pricing | ||||
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | 9,980,974 | See Plans and Pricing | See Plans and Pricing | ||||
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | 8,206,737 | See Plans and Pricing | See Plans and Pricing | ||||
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | 8,629,185 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Allergan Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | 7,033,605 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Allergan Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2005110424 | See Plans and Pricing |
| Japan | 2013511573 | See Plans and Pricing |
| Japan | 2022000441 | See Plans and Pricing |
| Japan | 6482547 | See Plans and Pricing |
| Japan | 6683787 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Allergan Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0660716 | 02C0033 | France | See Plans and Pricing | PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: |
| 0660716 | SPC/GB02/035 | United Kingdom | See Plans and Pricing | PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308 |
| 0660716 | C300099 | Netherlands | See Plans and Pricing | PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
